Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity
IntroductionDexrazoxane (DZR) has been used to prevent cardiotoxicity from doxorubicin (DOX), particularly in younger patients with cancer and those with pre-existing cardiac dysfunction. Herein, we sought to further define the role of DZR by evaluating its capacity to mitigate cardiotoxicity in pat...
Saved in:
| Main Authors: | Zachary M. Neiman, Carlo S. Legasto, Alan K. Chin, Tiffany Guan, Brian C. Schulte |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1621409/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01) -
Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
by: Hui-Ming Chang, et al.
Published: (2025-05-01) -
Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01) -
Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report
by: Nao Wakamiya, et al.
Published: (2025-06-01) -
Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)